Carvedilol Decrease IL-1β and TNF-α, Inhibits MMP-2, MMP-9, COX-2, and RANKL Expression, and Up-Regulates OPG in a Rat Model of Periodontitis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  de Araújo Júnior, Raimundo Fernandes ^a   Souza, Tatiana Oliveira ^b   de Medeiros, Caroline Addison Xavier ^c   de Souza, Lélia Batista ^a   de Freitas, Maria Lourdes ^a   de Lucena, Hévio Freitas ^a   do Socorro Costa Feitosa Alves, Maria ^a   de Araújo, Aurigena Antunes ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b Post Graduation Program Health Science UFRN and FACENE   (Brazil)

^c DEPARTAMENTO DE FÍSICA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CARDILOL; CARVEDILOL; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; GLUTATHIONE; INTERLEUKIN 1BETA; MALONALDEHYDE; MYELOPEROXIDASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BONE DESTRUCTION; BONE REMODELING; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME INHIBITION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OSSIFICATION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PERIODONTITIS; PROTECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; TREATMENT DURATION; UPREGULATION;

ANIMALS; CARBAZOLES; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; INTERLEUKIN-1BETA; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; OSTEOPROTEGERIN; OXIDATIVE STRESS; PERIODONTITIS; PROPANOLAMINES; RANK LIGAND; RATS; TUMOR NECROSIS FACTOR-ALPHA;

NEGIBACTERIA; RATTUS;

EID: 84879772484     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066391     Document Type: Article

References (26)

1. Marazzi G, Volterrani M, Caminiti G, Iaia L, Massaro R, et al. (2011) Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients. J Card Fail 17: 703-709.
2. Chen-Scarabelli C, Saravolatz L, Murad Y, Shieh WS, Qureshi W, et al. (2012) A critical review of the use of carvedilol in ischemic heart disease. Am J Cardiovasc Drugs 12: 391-401.
3. Yuan Z, Shioji K, Kihara Y, Takenaka H, Onozawa Y, et al. (2004) Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol 286: H83-90.
4. Akbas H, Ozden M, Kanko M, Maral H, Bulbul S, et al. (2005) Protective antioxidant effects of carvedilol in a rat model of ischaemia-reperfusion injury. J Int Med Res 33: 528-536.
5. Li B, Liao YH, Cheng X, Ge H, Guo H, et al. (2006) Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. International Journal of Cardiology 111: 247-255.
6. Kim YH, Park SM, Kim M, Kim SH, Lim SY, et al. (2012) Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats. Toxicol Mech Methods 22: 488-498.
7. Yue-Chun L, Li-Sha G, Jiang-Hua R, Peng-Lin Y, Jia-Feng L, et al. (2008) Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J Cardiovasc Pharmacol 51: 92-98.
8. Kowalski J, Blaszczyk J, Kowalski M, Ceglinski T, Wrobel W, et al. (2005) [Effect of carvedilol on lipid peroxidation in patients with stable angina]. Pol Merkur Lekarski 18: 156-159.
9. Kumar A, Dogra S, (2009) Neuroprotective effect of carvedilol, an adrenergic antagonist against colchicine induced cognitive impairment and oxidative damage in rat. Pharmacol Biochem Behav 92: 25-31.
10. Kowalski J, Banach M, Barylski M, Irzmanski R, Pawlicki L, (2008) Carvedilol modifies antioxidant status of patients with stable angina. Cell Mol Biol Lett 13: 230-239.
11. Goto S, Fujii H, Kono K, Nakai K, Hamada Y, et al. (2011) Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes. American Journal of Nephrology 34: 281-290.
12. Batista R, Rosetti EP, Zandonade E, Roelke LH, Vettore MV, et al. (2012) Association between periodontal disease and subclinical atherosclerosis: the ELSA-Brasil study. Cad Saude Publica 28: 965-976.
13. Miyaki K, Masaki K, Naito M, Naito T, Hoshi K, et al. (2006) Periodontal disease and atherosclerosis from the viewpoint of the relationship between community periodontal index of treatment needs and brachial-ankle pulse wave velocity. BMC Public Health 6: 131.
14. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, et al. (2006) Matrix metalloproteinase-2 and-9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovascular Research 69: 736-745.
15. Maeso G, Bravo M, Bascones A, (2007) Levels of metalloproteinase-2 and-9 and tissue inhibitor of matrix metalloproteinase-1 in gingival crevicular fluid of patients with periodontitis, gingivitis, and healthy gingiva. Quintessence International 38: 247-252.
16. Leitao RF, Ribeiro RA, Chaves HV, Rocha FA, Lima V, et al. (2005) Nitric oxide synthase inhibition prevents alveolar bone resorption in experimental periodontitis in rats. J Periodontol 76: 956-963.
17. Souza MH, Troncon LE, Cunha FQ, Oliveira RB, (2003) Decreased gastric tone and delayed gastric emptying precede neutrophil infiltration and mucosal lesion formation in indomethacin-induced gastric damage in rats. Brazilian Journal of Medical and Biological Research 36: 1383-1390.
18. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ, (1995) Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 115: 1265-1275.
19. Kendall C, Ionescu-Matiu I, Dreesman GR, (1983) Utilization of the biotin/avidin system to amplify the sensitivity of the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods 56: 329-339.
20. Pham CT, (2008) Neutrophil serine proteases fine-tune the inflammatory response. Int J Biochem Cell Biol 40: 1317-1333.
21. Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, et al. (1999) Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci U S A 96: 6261-6266.
22. Kaner D, Bernimoulin JP, Kleber BM, Heizmann WR, Friedmann A, (2006) Gingival crevicular fluid levels of calprotectin and myeloperoxidase during therapy for generalized aggressive periodontitis. Journal of Periodontal Research 41: 132-139.
23. Lorencini M, Silva JA, de la Hoz CL, Carvalho HF, Stach-Machado DR, (2009) Changes in MMPs and inflammatory cells in experimental gingivitis. Histol Histopathol 24: 157-166.
24. Xu L, Yu Z, Lee HM, Wolff MS, Golub LM, et al. (2008) Characteristics of collagenase-2 from gingival crevicular fluid and peri-implant sulcular fluid in periodontitis and peri-implantitis patients: pilot study. Acta Odontol Scand 66: 219-224.
25. Smith PC, Munoz VC, Collados L, Oyarzun AD, (2004) In situ detection of matrix metalloproteinase-9 (MMP-9) in gingival epithelium in human periodontal disease. Journal of Periodontal Research 39: 87-92.
26. Wu TC, Chen YH, Leu HB, Chen YL, Lin FY, et al. (2007) Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and-9 in experimental atherosclerosis. Free Radic Biol Med 43: 1508-1522.